Related Experiment Video

Updated: Aug 8, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific

W-F Cheng1, C-N Lee, Y-N Su

  • 1Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei.

Cancer Gene Therapy
|April 29, 2006
PubMed

Insights

This study developed a novel cancer vaccine using SIN replicon particles encoding calreticulin (CRT) linked to a tumor antigen. The vaccine significantly boosted anti-tumor immunity and protected mice against cancer.

Area of Science:

  • Oncolytic Virotherapy
  • Immunology
  • Vaccine Development

Background:

  • Alphavirus vectors, specifically SIN replicon particles, show promise for cancer vaccines and gene therapy.
  • Developing effective cancer vaccines requires strategies to enhance antigen presentation and stimulate robust immune responses.

Purpose of the Study:

  • To develop SIN replicon particles encoding calreticulin (CRT) linked to the human papillomavirus type 16 (HPV16) E7 protein for cancer immunotherapy.
  • To evaluate the efficacy of these novel vaccine particles in generating anti-tumor immunity and protection.

Main Methods:

  • Utilized a new packaging cell line (PCL) to generate replication-defective SIN replicon particles.
  • Constructed SINrep5-CRT/E7 particles linking CRT to the HPV16 E7 antigen.
  • Assessed T-cell responses, tumor growth inhibition, and long-term immunity in vaccinated mice.

Main Results:

  • SINrep5-CRT/E7 particles significantly increased E7-specific CD8(+) T-cell precursors.
  • Demonstrated a strong antitumor effect against E7-expressing tumors and reduced lung tumor nodules in mice.
  • Enhanced E7 antigen presentation via MHC class I pathway by direct DC infection and pulsing.
  • Generated long-term in vivo tumor protection and antigen-specific memory immunity.

Conclusions:

  • The CRT strategy within SIN replicon particles effectively generates potent anti-tumor immune responses.
  • This approach holds significant potential for developing advanced cancer vaccines for prophylaxis and immunotherapy.
  • Antiangiogenesis may contribute to the observed antitumor effects of the SINrep5-CRT/E7 vaccine.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Concept Videos

Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...